FCP
TVRD

Fidelis Capital Partners’s Tvardi Therapeutics TVRD Stock Holding History

Fidelis Capital Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-706
Closed -$23.1K – 409
2024
Q1 		$23.1K Buy
+706
New +$18.3K ﹤0.01% 370

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelis Capital Partners's TVRD Position: Q2 2024 in Review

Fidelis Capital Partners sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 706 shares — an estimated $23.1K sold.

Fidelis Capital Partners first reported a position in TVRD in Q1 2024 and held it in 1 quarter. The position peaked at $23.1K in Q1 2024. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • Fidelis Capital Partners reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Fidelis Capital Partners sold 706 Tvardi Therapeutics shares in Q2 2024, an estimated $23.1K.
  • Fidelis Capital Partners first reported a position in Tvardi Therapeutics in Q1 2024 and held it in 1 quarter.
  • Fidelis Capital Partners's Tvardi Therapeutics position peaked at $23.1K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on Fidelis Capital Partners's 13F filing for Q2 2024, filed 13 Aug 2024.